ACTRN12624000054516招募中1 期
A Phase 1, Randomized, Double-blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-9768 in Healthy Volunteers
Sanegene Bio New Zealand Ltd0 个研究点目标入组 36 人开始时间: 2024年1月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Male and female subjects aged 18 to 55 years are included at the time of informed consent.
- •2. Body mass index between 18 and 32 kg/m2 at screening, inclusive.
- •3. Physical examination, vital signs, 12-lead electrocardiogram, and laboratory tests be normal or slightly abnormal but not clinically significant according to Investigator’s judgement.
- •4. Healthy volunteers must be willing to be vaccinated for Neisseria meningitidis (both meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine), Haemophilus influenzae, and Streptococcus pneumoniae before dosing, and willing to receive prophylactic antibiotics as required in the protocol.
- •5. Female subjects must be non-pregnant or non-lactating.
- •6. Women of child-bearing potential who are not exclusively in same-sex relationships and males with partners of child-bearing potential must agree to use adequate contraception (As described in Appendix 1) from signing the informed consent until 12 weeks after completion of the follow-up visit.
- •7. Males must not donate sperm during the study and for 12 weeks after completion of the follow-up visit. Females must not donate egg and for12 weeks after completion of the follow-up visit.
- •8. Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.
排除标准
- •1. A history of or current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator’s judgment) or interfere with the subject’s participation in the clinical study.
- •2. History of or evidence of tuberculosis.
- •3. History of recurrent or chronic infections.
- •4. Subjects with a history of meningococcal infection, or subjects who are exposed to Neisseria meningitidis.
- •5. History of asplenia or splenectomy.
- •6. History of abnormalities in complement or hereditary complement deficiency.
- •7. History of receiving any type of live attenuated vaccine 30 days prior to screening or plans to have such a vaccination over the course of study.
- •8. Any skin condition and/or tattoo that may interfere the evaluation of safety at the injection site.
- •9. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection within 14 days before the first study drug administration.
- •10. History of clinically significant tendinopathy and/or tendon rupture.
- •11. Serum C3 less than LLN at screening.
- •12. Positive result of hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), human immunodeficiency virus (HIV) antibody, or syphilis at screening.
- •13. Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or gamma-glutamyl transferase (GGT) greater than 1.5 × ULN; or, if ALT, TBIL, AST, ALP, or GGT greater than ULN, and less than or equa to 1.5 × ULN, and considered clinically relevant by the Investigator at screening, Day -14, or Day -1.
- •14. Creatinine (Cr) greater than ULN at screening, Day -14, or Day -1, and considered clinically relevant by the Investigator.
- •15. QTcF values greater than 450ms for male, and greater than 470ms for female, confirmed by repeated ECGs at screening, Day -14, or Day -1.
- •16. History of multiple drug allergies or allergic reactions to an oligonucleotide or N-acetylgalactosamine (GalNAc).
- •17. History of intolerance to subcutaneous (SC) injection or relevant abdominal scarring (surgical, burns, etc.)
- •18. Received an investigational agent within 30 days or 5-half-lives (whichever is longer) before the first dose of the study drug or being in other clinical study.
- •19. History or clinical evidence of drug abuse within 12 months before screening or positive screen for drugs of abuse.
- •20. Used prescribed or over-the-counter medication within 14 days or 5 half-lives (whichever is longer) before the first dose of the study drug unless determined not clinically relevant by the Investigator.
- •21. Alcohol consumption more than 14 standard drinks per week within one month before screening or positive screen for an alcohol breath test (1 standard drink = 10 grams of alcohol).
- •22. Regular tobacco use more than 5 cigarettes per day within 3 months before screening.
- •23. Donate more than 500 mL of blood within 90 days before the first dose of the study drug.
- •24. Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject’s participation in or completion of the study.
研究者
相似试验
已完成
不适用
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single- and Multiple-Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-440 Alone and in Combination with VX-661/Ivacaftor, and Bioavailability and Food Effect of VX-440 in Healthy Adult Subjects10038686cystic fibrosisNL-OMON43882Vertex Pharmaceuticals120
尚未招募
1 期
A Study in Healthy Males and Females to Test How Different Doses of OPC-224333 are Tolerated (Arm 1)Neurological - EpilepsyEpilepsyACTRN12622000460707Otsuka Pharmaceutical Development & Commercialization, Inc72
尚未招募
不适用
A Phase 1 Study to Assess the Safety and Pharmacokinetics of GC1102 (Hepabig-Gene) in Healthy Male AdultsKCT0000473Green Cross33
已完成
1 期
A Phase 1, Single-Dose, Multiple-Dose, Food Effect and Drug-Drug Interaction Study of BPN14770Health ConditionJPRN-jRCT2031200182agata Tsutae112
招募中
不适用
A Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of PRAX-628 in Healthy Participants.Focal epilepsy10039911NL-OMON51482Praxis Precision Medicines112